BGNE : Insider Transactions for Beigene Ltd | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Beigene Ltd (BGNE)

$167.39

6.93 (3.98%) as of 4:30 Tue 5/21

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

90,630,000

Market Cap:

15.17(B)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$129.52 - $242.06

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 664

Guru Rank Value : 3

Guru Occurances : 1


6 Months 1 Year 2 Year

Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	100,397	100,397	5,364,251	5,588,274
Total Sell Value	$15,909,372	$15,909,372	$1,039,781,980	$1,085,894,829
Total People Sold	2	2	8	9
Total Sell Transactions	6	6	20	54
End Date	2024-02-22	2023-11-21	2023-05-23	2022-05-23

Adjust Filter Settings

Records found: 527

Page 16 of 22

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

CMO, Hematology

• – –

2019-03-11

4

AS

$130.00

$333,450

D/D

(2,565)

0

-

CMO, Hematology

• – –

2019-03-11

4

OE

$29.49

$75,642

D/D

2,565

2,565

-

CMO, Hematology

• – –

2019-03-07

4

AS

$140.50

$9,976

D/D

(71)

0

-

Chief Executive Officer

• • –

2019-03-06

4

AS

$150.00

$15,000

I/I

(100)

100

-

Chief Executive Officer

• • –

2019-03-05

4

AS

$150.55

$945,454

I/I

(6,230)

0

-

Chief Executive Officer

• • –

2019-03-05

4

AS

$151.54

$729,433

D/D

(4,791)

0

-

Chief Executive Officer

• • –

2019-03-04

4

AS

$150.77

$1,481,625

I/I

(9,790)

0

-

Chief Executive Officer

• • –

2019-03-04

4

AS

$151.34

$697,426

D/D

(4,588)

0

-

Director

– • –

2019-03-01

4

AS

$150.00

$150,000

D/D

(1,000)

0

-

Director

– • –

2019-03-01

4

AS

$138.53

$584,125

I/I

(4,000)

0

-

Peterson Amy C.

CMO, Immuno-oncology

• – –

2018-12-18

4

AS

$131.74

$1,356,312

D/D

(10,141)

0

-

Peterson Amy C.

CMO, Immuno-oncology

• – –

2018-12-18

4

OE

$29.10

$295,103

D/D

10,141

10,141

-

Peterson Amy C.

CMO, Immuno-oncology

• – –

2018-12-17

4

AS

$130.37

$1,317,224

D/D

(9,859)

0

-

Peterson Amy C.

CMO, Immuno-oncology

• – –

2018-12-17

4

OE

$29.10

$286,897

D/D

9,859

9,859

-

Chief Executive Officer

• • –

2018-12-10

4

AS

$133.57

$561,863

I/I

(4,138)

0

-

Director

– • –

2018-12-03

4

AS

$150.98

$762,061

D/D

(5,000)

0

-

Chief Executive Officer

• • –

2018-11-28

4

AS

$143.71

$1,304,862

I/I

(8,865)

4,138

-

Chief Executive Officer

• • –

2018-11-27

4

AS

$139.57

$1,626,743

I/I

(11,252)

13,003

-

Director

– • –

2018-11-27

4

GD

$0.00

$0

D/D

89,999

7,773,608

-

Chief Executive Officer

• • –

2018-11-26

4

AS

$134.98

$1,262,430

I/I

(9,078)

24,255

-

CMO, Hematology

• – –

2018-11-26

4

AS

$139.58

$418,750

D/D

(3,000)

0

-

CMO, Hematology

• – –

2018-11-26

4

OE

$29.49

$88,470

D/D

3,000

3,000

-

Glazer Donald W.

Director

– • –

2018-11-19

4

GD

$0.00

$0

D/D

9,414

4,127,526

-

Director

– • –

2018-11-19

4

AS

$122.55

$621,490

D/D

(5,000)

0

-

Peterson Amy C.

CMO, Immuno-oncology

• – –

2018-11-12

4

AS

$111.10

$1,360,349

D/D

(12,067)

0

-

527 Records found	Previous 10 11 12 13 14 15 16 17 18 19 Next	Page 16 of 22

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.